Caring Cross - CAR-T as a Potential Cure for HIV
Caring Cross is a non-profit organization working to accelerate the development of advanced medicines and increase access to cures for all patients. They are using the support of a community of healthcare professionals, scientists, and business leaders to develop new technologies and candidate medicines. Currently, they are focused on improving the accessibility, affordability, and applicability of CAR-T technology and stem cell gene therapy. This includes creating affordable solutions for CAR-T cell production, advancing a decentralized cell manufacturing model, and developing an anti-HIV CAR-T cell therapy and stem cell gene therapies for Sickle Cell Disease and Beta-Thalassemia.
#CaringCross
A growing community of healthcare professionals, scientists, engineers, community advocates, donors, investors, and business leaders is supporting Caring Cross, a 501(c)(3) non-profit, in its mission to accelerate the development of advanced medicines and increase access to cures for all patients. Currently, Caring Cross is working to improve the accessibility, affordability, and applicability of CAR-T technology and stem cell gene therapy through the development of affordable solutions for CAR-T cell production, advancement of a decentralized cell manufacturing model, and development of an anti-HIV CAR-T cell therapy and stem cell gene therapies for Sickle Cell Disease and Beta-Thalassemia.
Caring Cross is a non-profit that aims to speed up the development of advanced medicines and increase access to cures for all patients. They are being supported by a community of healthcare professionals and others. Caring Cross is currently working on CAR-T technology and stem cell gene therapy to make them more accessible, affordable, and practical. This includes creating affordable solutions for CAR-T cell production, advancing a decentralized cell manufacturing model, and developing therapies for HIV and blood disorders.
Caring Cross is a non-profit that wants to make advanced medicines and cures available to all patients. They have the support of many healthcare professionals and others. Right now, they are working to make CAR-T technology and stem cell gene therapy easier to use, more affordable, and more practical. This includes finding ways to make CAR-T cells cheaper to produce, improving a decentralized cell manufacturing model, and creating therapies for HIV and blood disorders.